MYGN Earnings Date: Nov 4, 2026 (Estimated) — Myriad Genetics, Inc.
NASDAQ · Healthcare · Diagnostics & Research
Updated
When is MYGN's next earnings date?
Myriad Genetics, Inc. (MYGN) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.17 on revenue of $191.3M.
How did MYGN do in its last earnings report?
In its most recent report on Jul 30, 2026 (Q2 2026), Myriad Genetics, Inc. posted EPS of -$0.25 versus the -$0.06 estimate, a miss of 316.7%. Revenue was $190.7M against a $205.9M estimate. The stock's 1-day post-earnings move was -46.7%.
How much does MYGN stock move after earnings?
MYGN beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 19.1% (up or down) in the day after earnings.
About Myriad Genetics, Inc.
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-30 | Q2 2026 | -0.06 | -0.25 | -316.67% | $190.7M | ❌ Miss | -46.74% | -40.78% | -41.15% |
| 2026-05-05 | Q1 2026 | -0.09 | -0.09 | +0.00% | $200.4M | ➖ Inline | -18.29% | -19.09% | -6.76% |
| 2026-02-23 | Q4 2025 | -0.05 | 0.04 | +180.00% | $209.8M | ✅ Beat | +1.14% | +14.38% | +5.25% |
| 2025-11-03 | Q3 2025 | -0.05 | 0.00 | +100.00% | $205.7M | ✅ Beat | -21.03% | -20.78% | -10.39% |
| 2025-08-05 | Q2 2025 | -0.05 | 0.05 | +200.00% | $213.1M | ✅ Beat | +46.51% | +55.81% | +75.45% |
| 2025-02-24 | Q4 2024 | 0.03 | 0.03 | +0.00% | $210.6M | ➖ Inline | -14.80% | -24.60% | -29.39% |
| 2024-11-07 | Q3 2024 | 0.02 | 0.06 | +200.00% | $213.3M | ✅ Beat | -1.47% | -11.26% | -15.79% |
| 2024-08-06 | Q2 2024 | -0.01 | 0.05 | +600.00% | $211.5M | ✅ Beat | +2.62% | +8.55% | +6.55% |
Showing last 8 quarters.
Revenue by segment & region
By region
Q2 FY26 · $227.5M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 94.2% | $214.3M | +8.1% | $195.5M | $181.6M | $198.2M | $191.7M |
| Non-US | 5.8% | $13.2M | -11.4% | $15.1M | $14.3M | $14.9M | $14.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.